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GUEST EDITORIAL 
Readers may have noticed a new 
healthcare catchphrase gracing magazine 
covers and even the front page of the New 
York Times: “personalized medicine.”1 But 
what does it mean and how will it change 
healthcare? According to the President’s 
Council of Advisors on Science and 
Technology, ‘Personalized medicine refers 
to the tailoring of medical treatment to the 
individual characteristics of each patient.’2 
Personalized medicine is important 
because of several emerging clinical and 
financial trends in healthcare. As a result, 
there is a strong impetus for personalized 
medicine, which can succeed if we can 
find a way to break down the silos that 
have traditionally separated clinical and 
financial world views.
The clinical trends important to 
personalized medicine are evidence-
based medicine, the genomic revolution, 
and big data. Evidence-based medicine 
is behind the push to reduce variation in 
care, making providers accountable for 
delivering treatments that are grounded 
in scientific evidence. The genomic 
revolution refers to our ability to quickly 
and cheaply sequence the human genome 
and to determine the biological basis of 
behavior and disease. Big data refers to 
our ability to create large data sets and 
implement automated systems, like IBM’s 
Watson, to sort through and make sense of 
all the information we collect.
Personalized medicine also capitalizes on 
emerging financial trends in healthcare–
pay for performance, bundled payments, 
and expansion of affordable care. Pay for 
performance is where the rubber meets 
the road for evidence based healthcare–no 
outcome, no income. Bundled payments 
refers to the recognition that medical care, 
like a hospitalization for a heart attack, 
should be paid for in a lump sum rather 
than as separate line item bills for the 
hospital stay, EKGs, and aspirin. The need 
to deliver affordable care is at the heart of 
Affordable Care Act, which aims to expand 
health insurance coverage to the uninsured 
by finding savings in other parts of the 
healthcare system. 
Personalized medicine ties together the 
clinical trends of evidence-based medicine, 
the genomic revolution, and big data with 
the financial trends of pay for performance, 
bundled payments, and expansion of 
affordable care. Evidence-based medicine 
gives payers reassurance that individuals 
are getting the most appropriate treatment 
based on published guidelines. Payment 
rates for the expected cost of an entire 
course of care should be as personalized 
as the treatments they finance, to ensure 
that provider compensation is adequate and 
provides the correct incentives–that will 
require smart bundled payments. Providers 
will collect data on their patients, compare 
outcomes to those in the published 
literature to benchmark their performance, 
and researchers can use the same data to 
refine the published literature on outcomes 
and costs for this population, i.e. big data. 
Payers could use the same data to provide 
extra incentives for high-performance 
care as demonstrated through superior 
outcomes, which is the goal of pay for 
performance. This process will ultimately 
save costs for patients and allow us to 
sustainably cover the entire population 
with health insurance, the essence of 
affordable care.
So what’s the problem? In our current 
fragmented, fee-for-service medical 
system, the vision I outlined has yet to 
become a reality. Personalized medicine 
is a bundled product. However, payers 
often pay for each diagnostic, drug, and 
device separately. We all know that the 
informatics needed to connect a diagnostic 
to the therapy regimen and outcomes 
just doesn’t exist in most healthcare 
environments. Finally, payers are wary 
of the idea of paying more upfront for a 
new technology that promises savings in 
the future—they are more comfortable 
focusing on the cost savings in the here and 
now by denying reimbursement for a new 
test outright, requiring prior authorizations, 
or a high degree of patient cost sharing in 
order to contain costs.
So what’s the solution? Well, we could 
wait for the integrated, affordable 
healthcare system of our dreams. If we 
are talking about today, however, and 
not the year 2100, the answer is to take 
a more integrated perspective. What 
will get payers to agree to pay for a new 
technology when technology has been at 
the heart of our cost containment crisis? 
Data that shows that personalized medicine 
can save costs by avoiding treatments that 
will not work. What will get providers to 
order those tests, and then actually use 
the results? Properly designed incentives 
that compare the expected outcomes 
and costs of care with patients’ actual 
experience. Patients will also need to be 
convinced of the need to become involved 
in personalized treatment decisions. High-
deductible cost sharing and opaque prices 
mean that patients are getting tired of 
being surprised with large bills for care 
that they consider necessary. The promise 
of personalized medicine rests on the 
ability of scientists and financial analysts 
to collaborate to deliver this critical 
information in an impactful way.
I have seen these issues play out on the 
ground level in my own research. In one 
recent study, funded by MDxHealth, 
I was part of a team that investigated 
the potential cost savings from a new 
technology for the problem of unnecessary 
prostate biopsies.3 MDxHealth’s product, 
ConfirmDx for prostate cancer, is designed 
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to reduce the cost associated with repeat 
biopsies to diagnose prostate cancer. 
Using a budget impact model, we found 
that there was the potential for the test 
to be cost saving when accounting for 
the costs of repeated biopsies and the 
costs of the side effects of this invasive 
diagnostic procedure. However, the 
potential for cost savings were limited by 
the need to conform to the one-year time 
horizon common in U.S. managed care. 
In addition, prospective trials that collect 
clinical and financial data on the outcomes 
and cost of care will be needed to convince 
payers and providers that our results are 
credible. New payment models are needed 
to correctly align the incentives of patients, 
providers, and payers so that the individual 
responsible for the cost of care shares in 
the benefits of any cost savings.
While there are barriers to studying and 
implementing personalized medicine, the 
underlying forces motivating this new 
platform for healthcare are even stronger. 
The questions of how much technology 
should cost, who should pay, and the 
value of any new technology have taken 
on a heightened significance in the age of 
tighter budgets. Personalized medicine 
holds the promise of moving from a world 
of reducing waste on average to reducing 
waste on a patient-by-patient basis, 
which means a much greater potential for 
savings. In order to realize this vision, it 
will be necessary to collect both clinical 
and financial evidence in order to make the 
case for personalized medicine. We can 
then achieve our goals of treating patients 
as individuals, and doing so at a price we 
can afford. 
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